A5032296928- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Drug-Induced Hepatotoxicity and Protection
- Liver Disease Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- vaccines and immunoinformatics approaches
- Cytomegalovirus and herpesvirus research
- Immune cells in cancer
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Drug Transport and Resistance Mechanisms
- interferon and immune responses
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Diabetes and associated disorders
- Cell Adhesion Molecules Research
- Chemokine receptors and signaling
- Immune Response and Inflammation
- Viral-associated cancers and disorders
- SARS-CoV-2 and COVID-19 Research
Hospital Universitario Virgen de las Nieves
2016-2025
Universidad de Granada
2014-2025
Instituto de Investigación Biosanitaria de Granada
2014-2025
Andalusian Institute of Sexology and Psychology
2014-2020
Complejo Hospitalario Universitario de Granada
2017
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2016
Universidad de Málaga
2016
Complejo Hospitalario Universitario de Albacete
2016
Instituto de Investigación Biomédica de Málaga
2016
Hospital General Universitario Morales Meseguer
2016
Cell surface expression of HLA class I/peptide complexes on tumor cells is a key step in the generation T-cell-based immune responses. Several genetic defects underlying lack I have been characterized. Here we describe another molecular mechanism that accounts for complete absence molecule line (MSR3-mel) derived from melanoma patient. Hypermethylation MSR3-mel DNA, specifically HLA-A and -B genes, was identified, which resulted loss heavy chain transcription. Treatment with demethylating...
Cancer cells escape T-cell-mediated destruction by losing human leukocyte antigen (HLA) class I expression via various mechanisms, including loss of beta2-microglobulin (β2m). Our study illustrates the immune HLA I-negative tumor and chronological sequence appearance β2m gene mutation in successive lesions obtained from a patient with metastatic melanoma. We observed gradual decrease consecutive few HLA-negative nodules primary emergence totally negative lesion at later stages disease....
// Lourdes Martín-Martín 1 , Antonio López Belén Vidriales 2 María Dolores Caballero António Silva Rodrigues 3 Silvia Inês Ferreira 4 Margarida Lima 5 Sérgio Almeida 6 Berta Valverde 7 Pilar Martínez 8 Ana Ferrer 9 Jorge Candeias 10 Francisco Ruíz-Cabello 11 Josefa Marco Buadesa 12 Amparo Sempere 13 Neus Villamor 14 Alberto Orfao 1, * Julia Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical of Salamanca (IBSAL) and Department Medicine Cytometry Service, University (USAL),...
Abstract: The mechanisms that lead to loss of MHC class I expression in different types tumors are not yet fully known. Accordingly, we studied colorectal carcinomas elucidate the specific evasion T‐cell immune response. We selected with total and 124 immunohistochemical staining anti‐HLA monoclonal antibodies (mAb). Fourteen (11%) exhibited a phenotype HLA loss. Microsatellite instability (MSI) analysis was also carried out same tumor samples. β 2 ‐microglobulin (β m), HLA‐A, B, C antigens,...
Abstract: Mutations have been identified in the β 2 ‐ microglobulin gene of tumor cells two metastatic melanoma patients who received immunizations with MAGE peptides. One mutation abolishes start codon whereas other introduces a premature stop codon. The second micro‐globulin allele both tumors appears to be lost on basis sequence data and loss microsatellite heterozygosity. lack product results absence HLA class I antigens surface cells. This may explain why progressed despite immunization...
Abstract: We analyzed the expression of HLA class I antigens in 78 tumor tissue samples obtained from patients diagnosed as having colorectal carcinomas. A broad panel mAbs defining monomorphic, locus‐specific and allele‐specific determinants was used. In addition, an antibody HLA‐C determinant (L31) also tested. Previous reports on these tumors indicated losses 30 to 40%. At least 73% present study had a detectable alteration. These altered phenotypes were classified total loss (18%)...
Downregulation of MHC class I expression is a widespread phenomenon used by tumor cells to escape antitumor T-cell-mediated immune responses. These alterations may play role in the clinical course disease. The aim our study was investigate molecular mechanism underlying absence HLA-class molecule bladder cancer cells. Microdissected tissues were characterized real-time quantitative PCR for HLA-ABC, beta2-microglobulin and members antigen processing machinery (APM) HLA molecules (LMP2, LMP7,...
Background and Aim The genotype-phenotype interaction in drug-induced liver injury (DILI) is a subject of growing interest. Previous studies have linked amoxicillin-clavulanate (AC) hepatotoxicity susceptibility to specific HLA alleles. In this study we aimed examine potential associations between class I II alleles AC DILI with regards phenotypic characteristics, severity time onset Spanish cases. Methods High resolution genotyping loci A, B, C, DRB1 DQB1 was performed 75 cases 885...
We wanted to analyze whether tumor HLA class I (HLA‐I) expression influences the pattern of immune cell infiltration and stromal reaction in microenvironment. Tumor tissues obtained from 57 patients diagnosed with lung carcinomas were analyzed for leukocyte infiltration. 28 out completely negative HLA‐I (49.1%) or showed a selective HLA‐A locus downregulation (three patients, 5.2%). In 26 tumors (47.8%) we detected positive but percentage cells between 10 25%. The phenotype was produced by...
Immune-checkpoint inhibitors show encouraging results in cancer treatment, but the clinical benefit is limited exclusively to a subset of patients. We analyzed density and composition tumor T-cell infiltration non-small-cell lung carcinoma (NSCLC) relation PD-L1 HLA class I (HLA-I) expression. found that positive HLA-I expression, independently on status, key factor determining increased immune infiltrate. When both markers were simultaneously, we identified four phenotypes co-expression....